Biologos Resources

The biopharmaceutical manufacturing landscape is evolving rapidly, driven by the rise of personalized therapies, technological advancements, and increasingly stringent regulatory requirements. While these innovations present exciting opportunities, they also introduce new complexities in scaling production, maintaining quality and compliance, and managing rising costs and logistics.

Cell and Gene Therapies (CGTs) represent one of the most transformative innovations in modern medicine, offering curative potential for previously untreatable diseases. Today, the CGT market is valued at $15.48 billion, and with breakthrough approvals, increased investment and a rapidly expanding pipeline, it is projected to grow to $28.9 billion by 2029 [1].